ABIVAX PUBLISHES REVIEW IN DRUG DISCOVERY TODAY ON MECHANISM OF ACTION AND TRANSFORMATIVE POTENTIAL OF ABX464 AS THERAPY FOR INFLAMMATORY DISEASES
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: "Our recent publication in Drug Discovery Today once again demonstrates the unique mechanism of action and transformative potential of our lead drug candidate ABX464 to effectively and durably treat chronic inflammatory diseases. We are therefore very much looking forward to seeing the results of our ongoing clinical trials which are expected in Q2 2021, namely the Phase 2b trial in UC, the Phase 2a trial in rheumatoid arthritis as well as the Phase 2b/3 study in Covid-19 disease with the objective to prevent hyper-inflammation in high-risk patients. We are also keen to initiate the pivotal Phase 2b/3 clinical study in Crohn's disease in the course of this year. The review, describing the potent anti-inflammatory pathways of ABX464, also backs our assumption of ABX464's blockbuster potential across various chronic inflammatory diseases. Abivax will therefore continue to investigate possible additional indications in which the molecule could substantially improve the lives of patients in need of new, efficient and long-term effective therapeutic options."
In clinical studies for the treatment of ulcerative colitis, ABX464 is the first-in-class small molecule that has shown to induce and upregulate a specific microRNA, miR-124, in human immune cells leading to a robust and long-lasting anti-inflammatory effect in UC patients. The review summarizes the multiple effects of ABX464 in dampening inflammatory processes through the downregulation of several critical pro-inflammatory cytokines and cells, like TNFa, IL-6, MCP-1, IL-17 and Th17+ cells, emphasizing the potential of Abivax's lead drug candidate as an efficient and long-term effective therapy for the treatment of inflammatory diseases.
"By increasing the expression of miR-124 in the immune system cells, ABX464 inhibits the excessive inflammatory response that causes inflammatory diseases, such as ulcerative colitis. The scientific publication shows that miR-124 acts as an endogenous regulator of inflammation that limits the activation of the signalling pathways which are responsible for the expression of pro-inflammatory cytokines," explained Prof. Jamal Tazi, Ph.D., Vice President Research at Abivax. "This is the reason why ABX464 treats the root cause of inflammation at the molecular level, and consequently explains its efficacy in inducing and maintaining the clinical remission that we observed in Phase 2a clinical trials in ulcerative colitis patients along with a good safety and tolerability profile."
About ABX464's Mechanism of Action ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties. ABX464 was shown to exert its anti-inflammatory effects through binding to the cap binding complex (CBC), which sits at the 5' end of every RNA molecule in the cell. By binding to the CBC, ABX464 reinforces the biological functions of CBC in cellular RNA biogenesis. Specifically, ABX464 enhances the selective splicing of a single long non-coding RNA to generate the anti-inflammatory microRNA, miR-124, which downregulates pro-inflammatory cytokines and chemokines like TNF-?, IL-6,MCP-1 and IL-17, as well as Th17+ cells thereby "putting a brake" on inflammation and suggesting broad potential as a novel anti-inflammatory therapeutic agent. A seven- to ten-fold increase in miRNA-124 levels was observed in colorectal biopsies of UC patients treated with ABX464. ABX464 does not impact the splicing of cellular genes.
About Abivax (www.abivax.com) Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mn?mo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.Contacts
Abivax Communications Regina Jehleregina.firstname.lastname@example.org?? +33 6 24 50 69 63 InvestorsLifeSci Advisors Chris Maggoschris@lifesciadvisors.com +41 79 367 6254 Press Relations & Investors EuropeMC Services AG Anne Henneckeanne.email@example.com +49 211 529 252 22 Public Relations FranceActifin Ghislaine Gasparettoggasparetto@actifin.fr +33 6 21 10 49 24 Public Relations FranceDGM Conseil Thomas Roborel de Climensthomasdeclimens@dgm-conseil.fr +33 6 14 50 15 84 Public Relations USA Rooney Partners LLC Marion Janicmjanic@rooneyco.com +1 212 223 4017 ?
DISCLAIMERThis press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorit? des March?s Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
05.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de